BioSpace News Archive

CytoSorbents Corporation (Nasdaq: CTSO) (the “Company”) a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat cytokine storm and deadly inflammation in critically-ill and cardiac surgery patients around the world, today announced that it has commenced a $ 40 million underwr

Pharmazz, Inc., a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat patients in critical care, announced that it has successfully received marketing authorization and is preparing to launch Lyfaquin ® (centhaquine), a novel resuscitative agent indicated for the treatment of p

Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”), a leader in the development of genetic risk assessment tests, today announced the closing of its previously announced registered direct offering of 1,025,000 American Depositary Shares (“ADSs”)

Vaccitech Ltd, a clinical-stage biopharmaceutical company developing immunotherapies to treat and prevent infectious diseases and cancer, today announces that Oxford University’s Jenner Institute and Oxford Vaccine Group have taken the next step towards the discovery of a safe, effective and accessible vaccine against coronavirus.

UCL Business (UCLB) and Apollo Therapeutics (Apollo), a pioneering collaboration between three global pharmaceutical companies and three UK university technology transfer offices, along with Deerfield Management Company, have completed the licensing of the first Apollo-supported project, a novel gene therapy programme developed at University College London (UCL).

BioNJ, Biocom, the California Life Sciences Association, the HINJ, LSPA, and the Michigan Biosciences Industry Association submitted comments to the CMS on a notice of proposed rulemaking impacting value-based purchasing agreements and other innovative solutions designed to provide patient access to, and purchasing agreements for, cutting edge therapies and cures.

EGF THERAMED HEALTH CORP. (CSE:TMED)(OTCQB:EVAHF)(FRA:AUHP) (the “Company”) announces that it will rely on the temporary relief granted pursuant to British Columbia Instrument 51-517 (Temporary Exemption from Certain Corporate Finance Requirements with Deadlines during the Period from June 2 to August 31, 2020) in respect of the filing of business acquisition reports (“BAR”) for its acquisition of a 30% equity interest in Pharmadelic Labs Corp.

AIDS Healthcare Foundation (AHF) today called on the members of the U.S. House of Representatives Subcommittee on Oversight and Investigations to ask tough questions of drug companies testifying on coronavirus vaccines tomorrow.

The U.S. Food and Drug Administration continued to take action in the ongoing response to the COVID-19 pandemic

Burning Rock Biotech Limited (NASDAQ: BNR) today announced that it plans to release its unaudited financial results for the second quarter of 2020 before the U.S. market opens on August 11, 2020.